Regulatory issues in female sexual dysfunction

Int J Impot Res. 2007 Sep-Oct;19(5):526-9. doi: 10.1038/sj.ijir.3901595.

Abstract

Female sexual dysfunction (FSD) remains an enigmatic area to some, a controversial area to others and the subject of continued, intense debate in the literature. Questions remain regarding the legitimacy of FSD as a bona fide disease; the definition of FSD; the methods of diagnosis; and, the treatment of FSD. In this timely perspective, Jean Fourcroy, Consultant in Urology, Endocrinology and Regulatory Issues, discusses the controversies that continue to plague FSD.

MeSH terms

  • Clinical Trials as Topic / standards
  • Female
  • Humans
  • Sexual Dysfunction, Physiological / diagnosis*
  • Sexual Dysfunction, Physiological / physiopathology
  • Sexual Dysfunction, Physiological / therapy
  • Sexual Dysfunctions, Psychological / diagnosis*
  • Sexual Dysfunctions, Psychological / physiopathology
  • Sexual Dysfunctions, Psychological / therapy
  • United States
  • United States Food and Drug Administration